Neurocrine v. Sandoz: 20-Patent Valbenazine Dispute Dismissed Without Prejudice
Neurocrine Biosciences brought a 20-patent infringement action in the Delaware District Court against Sandoz and affiliated entities over generic valbenazine tosylate capsules. The case was dismissed without prejudice by stipulation after 405 days, with the court retaining jurisdiction to resolve any disputes relating to the parties' resolution.
A 20-patent ANDA fight over valbenazine that ended by stipulation
On 26 August 2022, Neurocrine Biosciences, Inc. filed suit in the U.S. District Court for the District of Delaware against Sandoz, Inc., Sandoz International GmbH, Sandoz AG, Crystal Pharmaceutical (Suzhou) Co., Ltd., and Crystal Pharmatech Co., Ltd. The complaint asserted infringement of 20 U.S. patents directed to valbenazine tosylate capsules equivalent to 40 mg and 80 mg — the active pharmaceutical ingredient in Neurocrine's branded product. The case was assigned to Judge Maryellen Noreika.
The recorded basis of termination is 'Dismissed without Prejudice.' The docket order states that, under Federal Rules of Civil Procedure 41(a)(1)(A)(ii) and 41(c), all claims, counterclaims, and affirmative defenses were dismissed without prejudice and without costs, disbursements, or attorneys' fees to any party, by agreement among Neurocrine, Sandoz Inc., Crystal Pharmaceutical (Suzhou) Co., Ltd., and Crystal Pharmatech Co., Ltd. The order further states that the Delaware District Court retains jurisdiction to enforce and resolve any disputes relating to the parties' resolution of the actions.
The 405-day duration from filing to closure is relatively compact for a multi-defendant, 20-patent pharmaceutical dispute. The court's express retention of jurisdiction to enforce the parties' resolution is notable on the face of the order; beyond what the order states, the specific terms of the parties' resolution are not disclosed in the available record. What drove the early resolution — and whether any commercial arrangements underpin the stipulation — is not determinable from the public docket.
See Complete Case & Patent Analysis →Filing to Dismissed without Prejudice in 405 days
405 days from filing to closure — typical ANDA patent disputes often run 18–30 months
US10851104B2 and 19 further patents — valbenazine tosylate formulations
Any company developing, manufacturing, or supplying generic valbenazine tosylate capsules — including ANDA filers, API manufacturers, contract development and manufacturing organisations (CDMOs), and formulation partners — should conduct a freedom-to-operate analysis against all 20 patents asserted in this case. The without-prejudice dismissal means no court has invalidated or found non-infringement of any claim; the entire estate remains enforceable.
Official order — verbatim text
The stipulated order invokes Rule 41(a)(1)(A)(ii) and 41(c) to dismiss all claims, counterclaims, and affirmative defenses without prejudice and without costs. The explicit retention of court jurisdiction to enforce the parties' resolution distinguishes this order from a bare administrative closure, suggesting the parties reached some form of resolution — though its specific terms are not disclosed in the available record.
Dismissed without prejudice: what the stipulated exit means for both parties
Rule 41 stipulated dismissal without prejudice explained
A Rule 41(a)(1)(A)(ii) dismissal requires agreement of all parties who have appeared and, when filed, is self-executing. 'Without prejudice' means the dismissed claims are not adjudicated on the merits and are not barred by res judicata — Neurocrine retains the right to reassert the same patents if circumstances warrant. The court's retention of jurisdiction to enforce the parties' resolution is explicitly recorded in the order.
No merits adjudicationNeurocrine's patents remain live and re-assertable
Because the dismissal is without prejudice, all 20 asserted patents are unencumbered by any adverse judgment. Neurocrine preserves full enforcement optionality against Sandoz or any other generic filer. The court's retained jurisdiction clause also means Neurocrine can return to the Delaware forum to enforce any terms of the parties' resolution without initiating fresh proceedings, though those terms are not disclosed in the public record.
Patents survive, enforcement preservedSandoz and Crystal entities exit without an infringement finding
The Sandoz group and Crystal Pharmaceutical/Pharmatech entities are dismissed without any finding of infringement or validity ruling against them. No costs or fees were awarded. However, because the dismissal is without prejudice, no estoppel or preclusion shields them from a future action on these same patents. The specific terms of the parties' resolution — including any market-entry or licensing arrangements — are not disclosed in the available record.
No infringement finding; no preclusionGeneric valbenazine market entry remains legally unresolved on the merits
A without-prejudice dismissal creates no binding precedent on the validity or infringement of Neurocrine's 20 valbenazine patents. Other generic filers seeking to launch competing valbenazine products face the same portfolio without any court ruling weakening it. The breadth of the asserted estate — 20 patents spanning formulation and compound claims — continues to represent a substantial litigation risk for any ANDA filer in this space.
Patent estate intact; generic risk persistsFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Neurocrine Biosciences, Inc. | Company | /Search in Eureka ↗ |
| Defendant | Sandoz, Inc. | Company | /Search in Eureka ↗ |
| Co-Defendant | Sandoz International, GmbH | Company | Search in Eureka ↗ |
| Co-Defendant | Sandoz AG | Company | Search in Eureka ↗ |
| Co-Defendant | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Company | Search in Eureka ↗ |
| Co-Defendant | Crystal Pharmatech Co., Ltd. | Company | Search in Eureka ↗ |
| Plaintiff counsel | Andrew Colin Mayo | Attorney | Counsel for Neurocrine Biosciences, Inc.Search in Eureka ↗ |
| Plaintiff counsel | Steven J. Balick | Attorney | Counsel for Neurocrine Biosciences, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Ashby & Geddes PC | Law Firm | Representing Neurocrine Biosciences, Inc.Search in Eureka ↗ |
| Defendant counsel | Ronald P. Golden , III | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant counsel | Stephen B. Brauerman | Attorney | Counsel for Sandoz, Inc.Search in Eureka ↗ |
| Defendant law firm | Bayard PA | Law Firm | Representing Sandoz, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Maryellen Noreika | Judge | Delaware District CourtSearch in Eureka ↗ |
R&D signals in the valbenazine and VMAT2 inhibitor IP space
Forward-looking patent and R&D intelligence derived from Neurocrine Biosciences' 20-patent valbenazine estate and the competitive landscape around VMAT2 inhibitor therapies.
Neurocrine's valbenazine filing activity: lifecycle depth
Neurocrine has built a layered valbenazine estate stretching from early compound patents to dense clusters of formulation and polymorph filings through 2020–2021. Tracking continuation and continuation-in-part activity from the application numbers in this case reveals the current boundaries of the protected estate and signals where new claims may still be pending prosecution.
20-patent lifecycle estateVMAT2 inhibitor patent filing trends post-valbenazine approval
Following valbenazine's approval for tardive dyskinesia, patent filing activity in the VMAT2 inhibitor class has increased across multiple assignees. Monitoring filing trends in solid-state forms, sustained-release formulations, and combination therapies can reveal where the next generation of VMAT2 assets is being developed and where white space for differentiated formulations exists.
VMAT2 inhibitor filing surgeSandoz and Crystal Pharmatech: generic CNS pipeline signals
Crystal Pharmaceutical (Suzhou) and Crystal Pharmatech's involvement as defendants suggests active polymorph or API development activity around valbenazine. Examining their patent filings in solid-state chemistry and CNS API synthesis can reveal their generic pipeline priorities and whether they are building proprietary IP positions in VMAT2 inhibitor space beyond the Sandoz ANDA.
Generic API polymorph IPAdjacent VMAT2 formulation and delivery white space
Neurocrine's estate focuses heavily on the tosylate salt form and capsule dosage form. Adjacent opportunities may exist in alternative salt forms, modified-release delivery systems, and paediatric formulations for VMAT2 inhibitors that fall outside the current claim landscape. A landscape search can confirm whether these areas remain open for differentiated development.
Modified-release & salt form gapsSimilar ANDA patent infringement cases in Delaware — VMAT2 and CNS drugs
Explore related Hatch-Waxman patent infringement cases in the Delaware District Court involving CNS and movement-disorder drug portfolios with multi-patent assertions.
What this case signals for the valbenazine and VMAT2 inhibitor IP landscape
A 20-patent assertion dismissed in 405 days, with jurisdiction retained, raises pointed questions about generic market access and portfolio enforcement strategy.
Neurocrine's 20-patent estate signals deep formulation layering in valbenazine
Asserting 20 patents in a single ANDA case is consistent with a layered Orange Book strategy designed to maximise the litigation-stay period and deter generic entry. Companies operating in CNS/VMAT2 inhibitor space should map their own freedom-to-operate against the full Neurocrine portfolio, not just the lead compound patents.
Court's retained jurisdiction clause warrants close monitoring
The Delaware court's express retention of jurisdiction to enforce the parties' resolution is visible on the face of the order. Any subsequent motion practice in this docket — even after closure — could surface terms or obligations relevant to third parties assessing the competitive landscape for generic valbenazine.
Neurocrine v Sandoz — key questions answered
Neurocrine asserted 20 U.S. patents in Case No. 1:22-cv-01124, including US10851104B2, US11026931B2, US10906902B2, US10065952B2, US11040029B2, US10851103B2, US10919892B2, US11311532B2, US8039627B2, US8357697B2, and ten further patents. All relate to valbenazine tosylate capsules equivalent to 40 mg and 80 mg.
A dismissal without prejudice means no court ruled on the merits of infringement or validity. All 20 asserted patents remain enforceable. Neurocrine retains the right to bring a new action asserting the same patents against Sandoz or any other party. No res judicata or collateral estoppel effect arises from this dismissal.
The stipulated order expressly states that the U.S. District Court for the District of Delaware retains jurisdiction to enforce and resolve any disputes relating to the parties' resolution of the actions. This is a standard mechanism when parties reach a resolution they wish to be enforceable by the same court without filing a new lawsuit. The specific terms of the parties' resolution are not disclosed in the available public record.
The defendants were Sandoz, Inc., Sandoz International GmbH, Sandoz AG, Crystal Pharmaceutical (Suzhou) Co., Ltd., and Crystal Pharmatech Co., Ltd. Note that the Rule 41 stipulation on the docket names Sandoz Inc., Crystal Pharmaceutical (Suzhou) Co., Ltd., and Crystal Pharmatech Co., Ltd. as the stipulating parties; the public record does not separately confirm the status of Sandoz International GmbH and Sandoz AG in the final stipulation.
The product at issue was valbenazine tosylate capsules equivalent to 40 mg and 80 mg — the generic equivalent of Neurocrine's branded valbenazine product used in the treatment of tardive dyskinesia and related movement disorders. The case appears to have arisen under the Hatch-Waxman framework governing ANDA-based patent challenges.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.